Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
Understanding of the importance of the normal intestinal microbial community in regulating microbial homeostasis, host metabolism, adaptive immune responses, and gut barrier functions has opened up the possibility of manipulating the microbial composition to modulate the activity of various intestin...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/3/691 |
_version_ | 1797488713248276480 |
---|---|
author | Maroun Bou Zerdan Stephanie Niforatos Sandy Nasr Dayana Nasr Mulham Ombada Savio John Dibyendu Dutta Seah H. Lim |
author_facet | Maroun Bou Zerdan Stephanie Niforatos Sandy Nasr Dayana Nasr Mulham Ombada Savio John Dibyendu Dutta Seah H. Lim |
author_sort | Maroun Bou Zerdan |
collection | DOAJ |
description | Understanding of the importance of the normal intestinal microbial community in regulating microbial homeostasis, host metabolism, adaptive immune responses, and gut barrier functions has opened up the possibility of manipulating the microbial composition to modulate the activity of various intestinal and systemic diseases using fecal microbiota transplant (FMT). It is therefore not surprising that use of FMT, especially for treating relapsed/refractory <i>Clostridioides difficile</i> infections (CDI), has increased over the last decade. Due to the complexity associated with and treatment for these diseases, patients with hematologic and oncologic diseases are particularly susceptible to complications related to altered intestinal microbial composition. Therefore, they are an ideal population for exploring FMT as a therapeutic approach. However, there are inherent factors presenting as obstacles for the use of FMT in these patients. In this review paper, we discussed the principles and biologic effects of FMT, examined the factors rendering patients with hematologic and oncologic conditions to increased risks for relapsed/refractory CDI, explored ongoing FMT studies, and proposed novel uses for FMT in these groups of patients. Finally, we also addressed the challenges of applying FMT to these groups of patients and proposed ways to overcome these challenges. |
first_indexed | 2024-03-10T00:06:15Z |
format | Article |
id | doaj.art-669d46374dcc41d89b2cd935a42efcad |
institution | Directory Open Access Journal |
issn | 2072-6694 |
language | English |
last_indexed | 2024-03-10T00:06:15Z |
publishDate | 2022-01-01 |
publisher | MDPI AG |
record_format | Article |
series | Cancers |
spelling | doaj.art-669d46374dcc41d89b2cd935a42efcad2023-11-23T16:07:07ZengMDPI AGCancers2072-66942022-01-0114369110.3390/cancers14030691Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and PracticeMaroun Bou Zerdan0Stephanie Niforatos1Sandy Nasr2Dayana Nasr3Mulham Ombada4Savio John5Dibyendu Dutta6Seah H. Lim7Division of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USADivision of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USAUnderstanding of the importance of the normal intestinal microbial community in regulating microbial homeostasis, host metabolism, adaptive immune responses, and gut barrier functions has opened up the possibility of manipulating the microbial composition to modulate the activity of various intestinal and systemic diseases using fecal microbiota transplant (FMT). It is therefore not surprising that use of FMT, especially for treating relapsed/refractory <i>Clostridioides difficile</i> infections (CDI), has increased over the last decade. Due to the complexity associated with and treatment for these diseases, patients with hematologic and oncologic diseases are particularly susceptible to complications related to altered intestinal microbial composition. Therefore, they are an ideal population for exploring FMT as a therapeutic approach. However, there are inherent factors presenting as obstacles for the use of FMT in these patients. In this review paper, we discussed the principles and biologic effects of FMT, examined the factors rendering patients with hematologic and oncologic conditions to increased risks for relapsed/refractory CDI, explored ongoing FMT studies, and proposed novel uses for FMT in these groups of patients. Finally, we also addressed the challenges of applying FMT to these groups of patients and proposed ways to overcome these challenges.https://www.mdpi.com/2072-6694/14/3/691fecal microbiota transplanthematologic diseasesoncologic diseasesoutcomechallenges |
spellingShingle | Maroun Bou Zerdan Stephanie Niforatos Sandy Nasr Dayana Nasr Mulham Ombada Savio John Dibyendu Dutta Seah H. Lim Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice Cancers fecal microbiota transplant hematologic diseases oncologic diseases outcome challenges |
title | Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice |
title_full | Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice |
title_fullStr | Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice |
title_full_unstemmed | Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice |
title_short | Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice |
title_sort | fecal microbiota transplant for hematologic and oncologic diseases principle and practice |
topic | fecal microbiota transplant hematologic diseases oncologic diseases outcome challenges |
url | https://www.mdpi.com/2072-6694/14/3/691 |
work_keys_str_mv | AT marounbouzerdan fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice AT stephanieniforatos fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice AT sandynasr fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice AT dayananasr fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice AT mulhamombada fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice AT saviojohn fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice AT dibyendudutta fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice AT seahhlim fecalmicrobiotatransplantforhematologicandoncologicdiseasesprincipleandpractice |